| First Author | Park E | Year | 2011 |
| Journal | Blood | Volume | 118 |
| Issue | 8 | Pages | 2191-9 |
| PubMed ID | 21715311 | Mgi Jnum | J:176902 |
| Mgi Id | MGI:5293171 | Doi | 10.1182/blood-2011-04-351239 |
| Citation | Park E, et al. (2011) Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 118(8):2191-9 |
| abstractText | Relapse of drug-resistant acute lymphoblastic leukemia (ALL) has been associated with increased expression of survivin/BIRC5, an inhibitor of apoptosis protein, suggesting a survival advantage for ALL cells. In the present study, we report that inhibition of survivin in patient-derived ALL can eradicate leukemia. Targeting survivin with shRNA in combination with chemotherapy resulted in no detectable minimal residual disease in a xenograft model of primary ALL. Similarly, pharmacologic knock-down of survivin using EZN-3042, a novel locked nucleic acid antisense oligonucleotide, in combination with chemotherapy eliminated drug-resistant ALL cells. These findings show the importance of survivin expression in drug resistance and demonstrate that survivin inhibition may represent a powerful approach to overcoming drug resistance and preventing relapse in patients with ALL. |
